Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Atengen, Inc. logo — Precision Pan-Cancer Tumor Killing

Atengen, Inc.

Precision Pan-Cancer Tumor Killing

1 employees Health Care, Pharmaceutical

General Information

Company Name Atengen, Inc.
Employees 1
Industries Health Care, Pharmaceutical
Social

Get notified when Atengen, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Atengen, Inc.

Atengen, Inc. is a biotech startup focused on precision pan-cancer tumor killing. Their innovative therapeutic target is specifically expressed in tumor blood vessels of most types of solid tumors, distinguishing it from healthy organ blood vessels. Through cutting-edge technologies, Atengen has identified drug candidates that not only inhibit new blood vessel growth, but also lead to extensive tumor necrosis by targeting existing tumor blood vessels. This approach presents a significant breakthrough in the treatment of solid tumors, with the potential to revolutionize the field. As the company operates by targeting the tumor blood supply as opposed to the tumor cells directly, it can effectively address solid tumors in a tissue agnostic manner while maintaining a high level of specificity. However, there is not enough information available about the founding date, industries, headquarters, last investment, and last investment investors at this time.

Taxonomy: cancer therapy, tumor targeting, solid tumor treatment, precision medicine, drug development, therapeutic targeting, tumor necrosis, innovative technology, drug candidates, blood vessel targeting, tumor blood supply, tissue agnostic treatment, revolutionary treatment, biomedical innovation

No funding data available for Atengen, Inc. yet.

Get notified when Atengen, Inc. raises funding

Atengen, Inc. Alternatives & Competitors

Atengen, Inc. vs
CimCure B.V.
CimCure B.V. The Netherlands

Cancer immunotherapy for solid tumors.

Seed
10 employees
Health Care
Atengen, Inc. vs
Tarveda Therapeutics
Tarveda Therapeutics United States

To discover, develop and commercialize a new class of potent and selective precision oncology medici...

Unknown
5 employees
Biotechnology, Health Care
Atengen, Inc. vs
Huasaiboman Medical Cell Biology
Huasaiboman Medical Cell Biology

Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art...

Series A
Biotechnology, Life Sciences

FAQ About Atengen, Inc.

Precision Pan-Cancer Tumor Killing
Atengen, Inc. operates in the following industries: Health Care, Pharmaceutical.
Atengen, Inc. has approximately 1 employees.
Top alternatives and competitors to Atengen, Inc. include CimCure B.V., Tarveda Therapeutics, Huasaiboman Medical Cell Biology, Teclison, OncoSpherix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Atengen, Inc. and CimCure B.V. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Atengen, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy